I promise that I don't have a contract that specifies a minimum number of Salix Pharmaceuticals (NASDAQ: SLXP )
articles, but sometimes the news flow just seems to run that way.
After a vague announcement of positive phase 3 data on Xifaxan in IBS-D
on July 1 and the announcement of a tax inversion M&A transaction
with Cosmo Tech on July 9, management has
now announced a successful appeal to the FDA and the approval of sub-q
Relistor for opioid-induced constipation (or OIC) in patients with
chronic pain unrelated to cancer.
Read the full article here:
Can Anything Derail Salix Pharmaceuticals?
Showing posts with label Progenics. Show all posts
Showing posts with label Progenics. Show all posts
Monday, July 14, 2014
Wednesday, February 29, 2012
Seeking Alpha: What's It Going To Take To Get Salix Cheap?
For the most part, a company actually missing estimates on an operating basis and significantly increasing estimated expenses for the next year is enough to drive the stock down. Salix Pharmaceuticals (SLXP) is not an ordinary stock, though, and investors seem happy to look past the near-term turbulence in favor of the long-term opportunity in this focused specialty pharmaceutical company.
A Mixed End To The Fiscal Year
To its credit, if there's a good way to miss earnings, Salix pretty much found it. Revenue rose over 30% for the quarter (with sales of lead drug Xifaxan up 29%) and gross margins were flat. That the company exceeded estimates for SG&A spending and missed sell-side analyst estimates for operating income by about 10% was pretty much moot against the 40% overall growth and the ongoing momentum in its class-leading drug.
Read the full article here:
What's It Going To Take To Get Salix Cheap?
A Mixed End To The Fiscal Year
To its credit, if there's a good way to miss earnings, Salix pretty much found it. Revenue rose over 30% for the quarter (with sales of lead drug Xifaxan up 29%) and gross margins were flat. That the company exceeded estimates for SG&A spending and missed sell-side analyst estimates for operating income by about 10% was pretty much moot against the 40% overall growth and the ongoing momentum in its class-leading drug.
Read the full article here:
What's It Going To Take To Get Salix Cheap?
Wednesday, January 18, 2012
Investopedia: The Salix Story Keeps Improving
Investors have a solid dozen investment options in Big Pharma and hundreds of biotechs to choose from, but the specialty pharmaceutical space has always been a little thin. That gives Salix Pharmaceuticals (Nasdaq:SLXP) a little bit of scarcity value - it has excellent growth credentials but also some of the security that comes with patents and the requirement for rivals to go through the FDA approval process.
One Drug to Lead the Way
One of the problems with specialty pharmaceutical companies like Salix, Forest Labs (NYSE:FRX), and Endo Pharmaceuticals (Nasdaq:ENDP) is that they're often highly dependent on a very small number of drugs. For Salix, it's Xifaxam - a non-systemic antibiotic that works especially well in the GI system. Xifaxam is approved for traveler's diarrhea and hepatic encephalopathy (where it has orphan drug status) and currently contributes about two-thirds of the company's sales.
Please click the link for more:
http://stocks.investopedia.
One Drug to Lead the Way
One of the problems with specialty pharmaceutical companies like Salix, Forest Labs (NYSE:FRX), and Endo Pharmaceuticals (Nasdaq:ENDP) is that they're often highly dependent on a very small number of drugs. For Salix, it's Xifaxam - a non-systemic antibiotic that works especially well in the GI system. Xifaxam is approved for traveler's diarrhea and hepatic encephalopathy (where it has orphan drug status) and currently contributes about two-thirds of the company's sales.
Please click the link for more:
http://stocks.investopedia.
Monday, October 24, 2011
Seeking Alpha: Cubist Fills Its Sales Bag And Pipeline With Adolor
Stuck in a trading range for about five years, Cubist Pharmaceuticals (CBST) has had a pretty good year in 2011. The company resolved a patent dispute with Teva Pharmaceuticals (TEVA) on reasonably good terms, got some patent extensions that should further boost its profit potential on Cubicin, and struck marketing deals with Optimer (OPTR) and AstraZeneca (AZN) to make better use of its own sales force. But that's not all that's working in Cubist's favor recently. The company's pipeline has also come along nicely, as the Calixa deal has delivered two promising compounds, one of which is now in late-stage studies.
That said, it has not been all sweetness and light for Cubist. Investors have been troubled by this company's heavy reliance on Cubicin and the inevitable declines that are coming in operating income, to say nothing of the inefficiencies of operating a salesforce with few compounds to sell. Investors have been waiting for Cubist to do a deal or two and now management has done just that – giving the company an additional product to sell and also adding some clinical compounds outside of its core anti-infective space.
Click the link for the full story:
Cubist Fills Its Sales Bag And Pipeline With Adolor
That said, it has not been all sweetness and light for Cubist. Investors have been troubled by this company's heavy reliance on Cubicin and the inevitable declines that are coming in operating income, to say nothing of the inefficiencies of operating a salesforce with few compounds to sell. Investors have been waiting for Cubist to do a deal or two and now management has done just that – giving the company an additional product to sell and also adding some clinical compounds outside of its core anti-infective space.
Click the link for the full story:
Cubist Fills Its Sales Bag And Pipeline With Adolor
Thursday, March 3, 2011
Investopedia: Salix Proves There Is Still Growth In Pharma
For those investors bored or disgusted with the current theme in Big Pharma of minimal top-line growth and mass firings, maybe Salix Pharmaceuticals (Nasdaq:SLXP) can be an antidote. As Salix is ably demonstrating these days, it is still possible to launch new drugs and see solid growth as a result. Of course, Salix has the benefit of a tiny base from which to grow, but in a pharma world that is starved for growth, Salix may be looking increasingly appetizing.
An OK End to the Fiscal Year
Salix reported respectable results for the fourth quarter. Sales rose 69% from last year, as revenue from Xifaxan soared and has quickly become 70% of the company's overall business. The company saw a decent improvement in product gross margins and operating income reversed from a year-ago loss.
Looking out into 2011, management guided to $520 million in revenue - a level that was a bit lower than the Street's old number, but still representing over 50% year-on-year growth. (For more, see Can Earnings Guidance Accurately Predict The Future?)
Please continue through the following link:
http://stocks.investopedia.
An OK End to the Fiscal Year
Salix reported respectable results for the fourth quarter. Sales rose 69% from last year, as revenue from Xifaxan soared and has quickly become 70% of the company's overall business. The company saw a decent improvement in product gross margins and operating income reversed from a year-ago loss.
Looking out into 2011, management guided to $520 million in revenue - a level that was a bit lower than the Street's old number, but still representing over 50% year-on-year growth. (For more, see Can Earnings Guidance Accurately Predict The Future?)
Please continue through the following link:
http://stocks.investopedia.
Subscribe to:
Posts (Atom)